5.36 USD
▼-0.10-1.83%
盘后 5.98 0.00%
2026-09-15
市值
$201.51M
市盈率
—
EPS
-1.04
股息率
—
52 周区间
1.00 – 7.19
成交量
156.80K
Beta
-0.99
目标价
9.00
52W 低 1.0052W 高 7.19
价格走势
公司简介
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company’s initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials; and has ...